PL2588457T3 - Pochodne pirazolochinolinowe jako inhibitory dna-pk - Google Patents

Pochodne pirazolochinolinowe jako inhibitory dna-pk

Info

Publication number
PL2588457T3
PL2588457T3 PL11729377T PL11729377T PL2588457T3 PL 2588457 T3 PL2588457 T3 PL 2588457T3 PL 11729377 T PL11729377 T PL 11729377T PL 11729377 T PL11729377 T PL 11729377T PL 2588457 T3 PL2588457 T3 PL 2588457T3
Authority
PL
Poland
Prior art keywords
inhibitors
dna
pyrazoloquinoline derivatives
pyrazoloquinoline
derivatives
Prior art date
Application number
PL11729377T
Other languages
English (en)
Inventor
Thomas Fuchss
Werner Mederski
Frank Zenke
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL2588457T3 publication Critical patent/PL2588457T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL11729377T 2010-07-01 2011-06-24 Pochodne pirazolochinolinowe jako inhibitory dna-pk PL2588457T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010025786A DE102010025786A1 (de) 2010-07-01 2010-07-01 Pyrazolochinoline
PCT/EP2011/003127 WO2012000632A1 (de) 2010-07-01 2011-06-24 Pyrazolochinoline
EP11729377.9A EP2588457B1 (de) 2010-07-01 2011-06-24 Pyrazolochinolinderivate als dna-pk-inhibitoren

Publications (1)

Publication Number Publication Date
PL2588457T3 true PL2588457T3 (pl) 2015-04-30

Family

ID=44627920

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11729377T PL2588457T3 (pl) 2010-07-01 2011-06-24 Pochodne pirazolochinolinowe jako inhibitory dna-pk

Country Status (22)

Country Link
US (1) US8802712B2 (pl)
EP (1) EP2588457B1 (pl)
JP (1) JP5411393B2 (pl)
KR (1) KR101921764B1 (pl)
CN (1) CN103080092B (pl)
AU (1) AU2011273968B2 (pl)
BR (1) BR112012033425A2 (pl)
CA (1) CA2804069C (pl)
CY (1) CY1115974T1 (pl)
DE (1) DE102010025786A1 (pl)
DK (1) DK2588457T3 (pl)
EA (1) EA022430B1 (pl)
ES (1) ES2528447T3 (pl)
HR (1) HRP20150030T1 (pl)
IL (1) IL223872A (pl)
MX (1) MX2012014638A (pl)
PL (1) PL2588457T3 (pl)
PT (1) PT2588457E (pl)
RS (1) RS53831B1 (pl)
SG (1) SG186870A1 (pl)
SI (1) SI2588457T1 (pl)
WO (1) WO2012000632A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
US9464085B2 (en) * 2012-08-17 2016-10-11 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
US10874670B2 (en) 2017-01-09 2020-12-29 Impact Therapeutics, Inc. Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof
CN108295070B (zh) * 2018-01-08 2020-08-11 华中农业大学 一种喹啉衍生物在制备肿瘤抑制药物中的用途
EP3980080A1 (en) 2019-06-10 2022-04-13 Sutro Biopharma, Inc. Immunomodulator antibody drug conjugates and uses thereof
EP3980423A1 (en) 2019-06-10 2022-04-13 Sutro Biopharma, Inc. 5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
EP3983410A1 (en) * 2019-06-17 2022-04-20 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
US20230000982A1 (en) * 2019-09-25 2023-01-05 Korea Institute Of Radiological & Medical Sciences Composition for preventing or treating cancer, containing novel trifluoromethyl phenyl pyrazole derivative as active ingredient
KR102663365B1 (ko) * 2019-09-25 2024-05-08 한국원자력의학원 신규 트리플루오로메틸페닐피라졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9107070A (pt) 1990-11-06 1994-05-31 Pfizer Processo para a preparação de derivados de quinazolina uteis para melhorar a atividade antitumoral.
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
US7872014B2 (en) * 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1910365A4 (en) * 2005-07-22 2009-07-15 Merck & Co Inc INHIBITORS OF CHECKPOINT KINASES
EP2303890A4 (en) 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
JP2012502067A (ja) * 2008-09-10 2012-01-26 カリプシス・インコーポレーテッド 疾患の治療のためのヒスタミン受容体の複素環阻害剤

Also Published As

Publication number Publication date
CA2804069C (en) 2018-06-12
EA022430B1 (ru) 2015-12-30
KR101921764B1 (ko) 2018-11-23
PT2588457E (pt) 2015-02-05
DK2588457T3 (en) 2015-01-12
CN103080092A (zh) 2013-05-01
RS53831B1 (sr) 2015-06-30
ES2528447T3 (es) 2015-02-10
AU2011273968B2 (en) 2014-11-20
CY1115974T1 (el) 2017-01-25
IL223872A (en) 2016-02-29
EA201300073A1 (ru) 2013-11-29
JP2013531663A (ja) 2013-08-08
SG186870A1 (en) 2013-02-28
HK1184782A1 (en) 2014-01-30
AU2011273968A1 (en) 2013-02-14
DE102010025786A1 (de) 2012-01-05
US8802712B2 (en) 2014-08-12
KR20130041139A (ko) 2013-04-24
CN103080092B (zh) 2014-12-17
MX2012014638A (es) 2013-02-07
EP2588457B1 (de) 2014-11-05
JP5411393B2 (ja) 2014-02-12
US20130150359A1 (en) 2013-06-13
CA2804069A1 (en) 2012-01-05
HRP20150030T1 (hr) 2015-03-13
WO2012000632A1 (de) 2012-01-05
EP2588457A1 (de) 2013-05-08
BR112012033425A2 (pt) 2020-08-18
SI2588457T1 (sl) 2015-03-31

Similar Documents

Publication Publication Date Title
SI2769980T1 (sl) Derivati pirazolokinolina kot inhibitorji PDE9
IL221823A (en) Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
IL252108A0 (en) cdk inhibitors
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
ZA201407554B (en) Dna-pk inhibitors
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
EP2576552A4 (en) BENZOQUINOLONE INHIBITORS OF VMAT2
SI2588457T1 (sl) Derivati pirazolokinolina kot inhibitorji dna pk
ZA201203326B (en) Imidazopyridine derivatives as jak inhibitors
GB201004179D0 (en) Enzyme inhibitors
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
GB201004178D0 (en) Enzyme inhibitors
PL2606034T3 (pl) Pochodne pirymidynowe jako inhibitory fak
ZA201206456B (en) Uses of dgati inhibitors
GB201016880D0 (en) Phosphodiesterase inhibitors
GB201009731D0 (en) Kinase inhibitors
SG11201503977PA (en) Azaindole derivatives as jak3 inhibitors
ZA201404533B (en) Quinoline derivatives as pde10a enzyme inhibitors
AU2019222801A1 (en) Glucosylceramide synthase inhibitors
AU2018200675A1 (en) Glucosylceramide synthase inhibitors
GB201018597D0 (en) Inhibitors
GB201003502D0 (en) Novel inhibitors
GB201003936D0 (en) Novel inhibitors
GB201006605D0 (en) Novel inhibitors